Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-α

Blood

Volumn 97, Issue 11, 2001, Pages 3648-3650

  Schmidt, Manuel ^a,b,c   Hochhaus, Andreas ^a,b,c   Nitsche, Andreas ^a,b,c   Hehlmann, Rüdiger ^a,b,c   Neubauer, Andreas ^a,b,c  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; BETA ACTIN; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; MESSENGER RNA; TRANSCRIPTION FACTOR;

ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; FOLLOW UP; GENE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK; SURVIVAL;

EID: 0035383797     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.11.3648     Document Type: Article

References (21)

1. Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;40:1330-1340.
2. Tura S, Baccarani M, Zuffa E, et al. Interferon alpha-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med. 1994;330:820-825.
3. Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood. 1994;84:4064-4077.
4. Allan NC, Richards SM, Shepherd PCA. UK Medical Research Council randomized multicentre trial of interferon-alpha n1 for chronic myeloid leukemia: improved survival irrespective of cytogenetic response. Lancet. 1995;345:1392-1397.
5. Kantarjian H, O'Brien S, Anderlini P, Talpaz M. Treatment of myelogenous leukemia: current status and investigational options. Blood. 1996;87: 3069-3081.
6. Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med. 1997;337:223-229.
7. Petska S, Langer JA, Zoon KC, Samuel CE. Interferons and their actions. Annu Rev Biochem. 1987;56:727-777.
8. Tanaka N, Taniguchi T. Cytokine gene regulation: regulatory cis elements and DNA binding factors involved in the interferon system. Adv Immunol. 1992;52:263-281.
9. Schindler C, Darnell JE Jr. Transcriptional responses to polypeptide ligands: the Jak-STAT pathway. Annu Rev Biochem. 1995;64:621-651.
10. Darnell JE Jr. STATs and gene regulation. Science. 1997;277:1630-1635.
11. Driggers PH, Ennist DL, Gleason SL, et al. An interferon γ-regulated protein that binds the interferon-inducible enhancer-element of major histocompatibility complex class I genes. Proc Natl Acad Sci U S A. 1990;87:3743-3747.
12. Weisz A, Marx P, Sharf R, et al. Human interferon consensus sequence binding protein is a negative regulator of enhancer elements common to interferon-inducible genes. J Biol Chem. 1992; 267:25589-25596.
13. Nelson N, Kanno Y, Hong C, et al. Expression of interferon regulatory factor family proteins in lymphocytes: induction of Stat 1 and ICSBP expression by T cell activation. J Immunol. 1996;156: 3711-3720.
14. Holtschke T, Löhler J, Kanno Y, et al. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell. 1996;87:307-317.
15. Schmidt M, Nagel S, Proba J, et al. Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. Blood. 1998;91:22-29.
16. Nitsche A, Steuer N, Schmidt CA, Landt O, Siegert W. Different real-time PCR formats compared for the quantitative detection of human cytomegalovirus DNA. Clin Chem. 1999;45:1932-1937.
17. Kreuzer KA, Lass U, Landt O, et al. Highly sensitive and specific fluorescence reverse transcription-PCR assay for the pseudogene-free detection of beta-actin transcripts as quantitative reference. Clin Chem. 1999;45:297-300.
18. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood. 1984;63:789-799.
19. Hochhaus A, Yan XH, Willer A, et al. Expression of interferon regulatory factor (IRF) genes and response to interferon-α in chronic myeloid leukemia. Leukemia. 1997;11:933-939.
20. Zhang X, Ren R. Bcr-abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood. 1998; 92:3829-3840.
21. Hao SX, Ren R. Expression of interferon consensus sequence binding protein (ICSBP) is down-regulated in bcr-abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits bcr-abl-induced myeloproliferative disorder. Mol Cell Biol. 2000; 20:1149-1161.